about
Assessment of the upper motor neuron in amyotrophic lateral sclerosisDifferentiating lower motor neuron syndromesThe autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of diseaseThe Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platformAmyotrophic lateral sclerosis and motor neuron syndromes in Asia.Cervical nerve root stimulation. Part I: technical aspects and normal data.Anterior interosseous nerve conduction study: normative data.Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data.Emerging therapies and challenges in spinal muscular atrophyMultiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryUtility of dissociated intrinsic hand muscle atrophy in the diagnosis of amyotrophic lateral sclerosisCorticomotoneuronal function and hyperexcitability in acquired neuromyotonia.Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisQuantifying disease progression in amyotrophic lateral sclerosis.Dissecting the mechanisms underlying short-interval intracortical inhibition using exercise.Motor cortical function and the precision gripApraxia and motor dysfunction in corticobasal syndrome.Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophyControversies and priorities in amyotrophic lateral sclerosis.Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosisAbnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosisData characterizing the ZMIZ1 molecular phenotype of multiple sclerosisFlecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.Cortical Function in Asymptomatic Carriers and Patients With C9orf72 Amyotrophic Lateral SclerosisDissociation of Structural and Functional Integrities of the Motor System in Amyotrophic Lateral Sclerosis and Behavioral-Variant Frontotemporal Dementia.Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights.Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis.Guillain-Barré syndrome: an update.Cortical dysfunction underlies the development of the split-hand in amyotrophic lateral sclerosis.Fatigue in multiple sclerosis: mechanisms and management.Riluzole, neuroprotection and amyotrophic lateral sclerosis.The puzzling case of hyperexcitability in amyotrophic lateral sclerosis.Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology.Guillain-Barré syndrome in Asia.Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies.Biomarkers and future targets for development in amyotrophic lateral sclerosis.
P50
Q26747024-B9306103-92B1-4FDE-BA69-A15F0E40ECC3Q28070092-E2A7B212-7F5D-4454-968B-F47568439DEAQ28307281-2C427C44-5DEC-465E-A977-1A119C975C72Q28488248-18D374E9-E78E-4525-AF8F-627CBBD4D1E2Q30251559-52CB2427-87E4-41C0-8210-6CA6DD8C3BF8Q31029199-EECECB83-C4F3-47B1-B29B-BA4C9B456922Q31060469-00F07C6D-2D93-4709-9845-046EC856B26DQ31099553-BDF16A46-2CD5-4979-B79C-71FFC9F0BF3BQ33578135-88B148B0-3C80-4DB7-9284-C33E6A9DD059Q33613668-5EA89725-8839-4731-BCBA-FCF7F7DE22B2Q34009478-02969052-7314-41CE-AA36-13F18B065CA9Q34088650-EDD3E636-0A77-4B40-87CE-C40A5E4F6AAEQ34431835-6A8CDBBC-B8FA-42DA-86A5-97866196B31AQ34737478-5DD12253-3600-4947-8E6F-17F9C9125202Q35008605-D4506E68-8B76-4DA2-85DD-7C6D6853564AQ35050099-A42E449F-B3C7-48A0-823D-4A383788CC92Q35094109-FBFDE35A-CF1C-4086-8C6B-087B39A7A3D9Q35130186-57DDE376-4D42-4311-881C-0AFC43B5826EQ35540059-C56ED4DA-E274-4F23-A272-45EE31165835Q36045826-76B7CDD5-8ACF-46FA-A384-A727A08AFD7FQ36226795-677BD932-71D7-4850-A0B8-48F1195E9258Q36227125-8C15A04B-92DE-4646-825A-45D0E1BBA33EQ36301650-B5D995D8-B3A7-4546-8C6F-4813701C4C3FQ36437641-CB22F4E0-9B27-448B-B0E5-5A58C7F12619Q36447450-BF1694B7-C262-441C-9E2E-2D92FDC92445Q36789553-D79C5295-8476-4E81-B2FE-B90311E7A884Q37206683-70BAEAEF-CE67-4B40-8692-7B8B6D30C2CEQ37312624-BB9545C1-F5A8-4E1D-B46F-805313638FD1Q37322100-60AF3CE6-4392-44BD-BBA8-1DA1D241E256Q37339743-F5EB6570-CE31-4ACE-A190-3088A4C16829Q37438170-F27E995B-F62B-4616-8A57-B4071529EEAEQ37438953-64DCC59A-CE4D-47D4-8DC8-9C0B28B943ECQ37514514-75A4DD2B-644F-43CA-AC4C-947C076BDF7BQ37681178-25DCA037-F40A-4F80-BBC5-284651C46F7AQ37727244-FF2C896C-A353-4A1E-BCE0-335D6829FDE4Q38102695-0302BDC1-8EAB-416E-A7DC-2E82890B0387Q38151353-D4382E97-7F5F-4636-BB85-D9CF940D2E72Q38172906-7E6C87B8-CBB9-4F69-9BCC-E078DDCBF432Q38220095-B00F7F3C-C909-4B41-B7CA-DB04EC09567AQ38220663-59C788F7-873C-4E35-8785-BBF7C87A6103
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Steve Vucic
@en
Steve Vucic
@nl
type
label
Steve Vucic
@en
Steve Vucic
@nl
altLabel
Vucic S
@en
prefLabel
Steve Vucic
@en
Steve Vucic
@nl
P31
P496
0000-0002-8323-873X